Effects of hypoglycemia on myocardial susceptibility to ischemia –reperfusion injury and preconditioning in hearts from rats with and without type 2 diabetes
Hypoglycemia is associated with increased mortality rate in patients with diabetes. The underlying mechanisms may involve reduced myocardial tolerance to ischemia and reperfusion (IR) or reduced capacity for i...
New classes of drugs to treat type 2 diabetes are continually being developed and marketed. The FDA has issued guidance to the pharmaceutical industry that newer hypoglycemic agents should not be associated with unacceptable increases in cardiovascular risk. To date, five trials have assessed specific cardiovascular endpoints for these newer agents. Empagliflozin and liraglutide have been found to improve cardiovascular outcomes.
The objective of the present study was to evaluate the possible inhibitory effect of sulfonylureas and non‐steroidal anti‐inflammatory drugs (NSAIDs) on canagliflozin metabolism in vitro. Three sulfonylurea derivatives were evaluated as inhibitors: chlorpropamide, glimepiride and gliclazide. Two other NSAIDs were used as positive control inhibitors: niflumic acid and diclofenac. The rate of formation of canagliflozin metabolites was determined by HPLC analysis of in vitro incubations of canagliflozin as a substrate with and without inhibitors, using human liver microsomes (HLMs). Among sulfonylureas, glimepiride showed...
Publication date: Available online 21 February 2018 Source:Journal of the Formosan Medical Association Author(s): Yi-Hsin Lin Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are the newest class of oral antidiabetic drugs (OADs), approved to be a second-line OAD for type 2 diabetes in Taiwan since 2016. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) had both released statements associating the use of SGLT-2 inhibitors may increase the risk of eu-glycemic diabetic ketoacidosis (euDKA). This review reveals the possible pathophysiology with a chain of metabolic adaptions to decrease pl...
Thomas Nystr öm, Irene Santos-Pardo, Fredric Hedberg, Johan Wardell, Nils Witt, Yang Cao, Leif Bojö, Bo Nilsson, Johan Jendle
In conclusion, SGLT2i reduced not only HbA1c, BW and BMI but also AHI significantly and therefore has potential as an effective treatment of OSAS. PMID: 29459554 [PubMed - as supplied by publisher]
The more often people worked nights, the more likely they were to have Type 2 diabetes.
Conclusion: The allele frequency of SLC22A1 gene rs628031 in Javanese-Indonesian population was almost the same as those found in Afro-American population as well as in other Asian populations. Similar results were obtained when the A allele frequency of SLC47A1 rs2289669 was compared to those in Chinese population. Further studies are recommended to examine the correlation between these polymorphisms and the variability of pharmacokinetic profiles as well as glycemic response to metformin and its adverse reactions.
Conclusion: PROVALID will provide information on incidence and progression of renal and cardiovascular disease and therapy in patients with type 2 diabetes mellitus in different European countries. Thus, in contrast to many other cohort studies we will be able to associate national clinical practise pattern with outcome in this highly vulnerable patient population.Kidney Blood Press Res 2018;43:181 –190
DIABETES type 2 symptoms can include feeling very thirsty, being very tired, or unexplained weight loss. But, you could lower your blood sugar by adding these supplements to your diet everyday, it ’s been revealed.
This article is protected by copyright. All rights reserved.